Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3BS97)

Drug Name

Macrolides Drug Info

Synonyms

Tylosin; tylosin tartrate; Tilosina; Tylosinum; UNII-YEF4JXN031; Tylosine; Tylocine; Tylan; Tylosin A; 1401-69-0; YEF4JXN031; Fradizine; CHEBI:17658; Vubityl 200; Tylosinum [INN-Latin]; Tylosine [INN-French]; Tilosina [INN-Spanish]; HSDB 7022; EINECS 215-754-8; AI3-29799; SR-05000002057; Tylosin [USP:INN:BAN]; Tylan (TN); Tylosin (USP/INN); AC1NQX0W

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]

Cross-matching ID

PubChem CID: 5280440
ChEBI ID: CHEBI:17658
CAS Number: CAS 1401-69-0
TTD Drug ID: DM3BS97

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Bacterial 23S ribosomal RNA (Bact 23S rRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lopinavir	DMITQS0	Human immunodeficiency virus infection	1C62	Approved	[2]
Chloramphenicol	DMFXEWT	Bacterial infection	1A00-1C4Z	Approved	[3]
Thiamphenicol	DMDRKH2	Bacterial infection	1A00-1C4Z	Approved	[4]
Lefamulin	DME6G97	Community-acquired pneumonia	CA40.Z	Approved	[5]
Linezolid	DMGFPU2	Bacteremia	1A73	Approved	[6]
Spiramycin	DM20R5F	Bacterial infection	1A00-1C4Z	Approved	[7]
Cethromycin	DMIGX84	Bacterial infection	1A00-1C4Z	Phase 3	[8]
Oxazolidinones	DMBM47Z	Gram-positive bacterial infection	1B74-1G40	Phase 2	[9]
EDP-420	DM5WZ0O	Bacterial infection	1A00-1C4Z	Phase 2	[10]
Micrococcin	DMJ4D1P	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial 23S ribosomal RNA (Bact 23S rRNA)	TTLFGBV	NOUNIPROTAC	Binder	[1]

------------------------------------------------------------------------------------

References

1	Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
2	Company report (JMI Laboratories)
3	Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol. 2004 Dec;54(5):1287-94.
4	The fused TrpEG from Streptomyces venezuelae is an anthranilate synthase, not a 2-amino-2-deoxyisochorismate [corrected] (ADIC) synthase. Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-9-13.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
6	Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23.
7	The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
8	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
9	Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA. 1999 Jul;5(7):939-46.
10	EDP-420, a Bicyclolide (Bridged Bicyclic Macrolide), Is Active against Mycobacterium avium. Antimicrob Agents Chemother. 2007 May; 51(5): 1666-1670.